# Olmesartan

Drug · id `cardio:olmesartan` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Benicar; Olmesartan medoxomil

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

Olmesartan is an ARB (angiotensin II receptor blocker), a medicine taken by mouth. The US label read, for Benicar tablets (olmesartan medoxomil), lists one use: treating high blood pressure in adults and in children six years of age and older. Benicar is the brand name on the label read.

## Technical summary

RxNorm ingredient 321064; UNII 6M97XTV3HD. The label names the substance as olmesartan medoxomil, a prodrug that the label says is hydrolyzed to olmesartan, so UNII 6M97XTV3HD is the UNII of the medoxomil ester and is a broad match. MeSH descriptor D000068557 is Olmesartan Medoxomil, also a broad match. Class: Angiotensin 2 Receptor Blocker (FDA established pharmacologic class, RxClass). The label read is the Cosette Pharmaceuticals, Inc. label for Benicar (olmesartan medoxomil) tablets, application NDA021286, effective 2025-09-23 in openFDA; Drugs@FDA lists the application's sponsor as COSETTE. The older Benicar label with set id 5b6f8a18 (dated 2023-07-12), generic olmesartan labels and the Benicar HCT combination labels were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Adults for whom the US label of olmesartan (Benicar) lists an indication: hypertension

Recipient: Adult; Population: Adult patients described in the indications section of the label. The hypertension sentence also names children six years of age and older, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passage read states; Follow-up: Not applicable (label statement)

### The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in adults, to lower blood pressure (the same label sentence also names children six years of age and older, recorded separately).

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Adult patients described in the indications section of the label. The hypertension sentence also names children six years of age and older, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults, as the passage read states; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective\_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:18:50Z. Source state: Current. Version fingerprint: 380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Background: openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective\_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:50Z. Source state: Current. Version fingerprint: 380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61.
     How it applies: Effective date of the label text read, 20250923.
  3. Background: openFDA Drugs@FDA record for application NDA021286 (BENICAR, sponsor COSETTE): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA021286, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021286%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:33Z. Source state: Current. Version fingerprint: ada3a2c27b76f10d908badc757070fe0fffe28b6cfbafef3ceaac5819a15264f.
     How it applies: Drugs@FDA product listing for application NDA021286, which confirms the product the label belongs to.

## Context: Children for whom the US label of olmesartan (Benicar) lists hypertension as an indication: children six years of age and older

Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children six years of age and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Benicar (olmesartan medoxomil) tablets, in the Cosette Pharmaceuticals, Inc. version dated 2025-09-23 in openFDA, lists the medicine for the treatment of hypertension in children six years of age and older, to lower blood pressure.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: children six years of age and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective\_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:18:50Z. Source state: Current. Version fingerprint: 380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61.
     How it applies: The label sentence that names children in the hypertension indication, quoted in the research quote table.
  2. Background: openFDA drug label record for Benicar (olmesartan medoxomil) tablets, Cosette Pharmaceuticals, Inc. label: indications and substance identifiers (Regulator, edition The openFDA drug label record for set id dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df (manufacturer Cosette Pharmaceuticals, Inc., application NDA021286), returned on 2026-11-09. The label text is dated 2025-09-23 (effective\_time). Other openFDA records of olmesartan labels from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22dc3f1fd4-5578-4c5d-be7b-12e3f8f3e7df%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:18:50Z. Source state: Current. Version fingerprint: 380c37611f59712fc5101ea575899a00a47645d1b8c2f1a05d5d9ec6c3edbd61.
     How it applies: Effective date of the label text read, 20250923.

## Connected pages

- Olmesartan is an ARB (FDA established pharmacologic class in RxClass): Angiotensin receptor blockers (ARBs) (`cardio:angiotensin-receptor-blockers-arbs`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-olmesartan-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 4 registry products
- 13 registry trials

## Provenance

Content hash: d53eb236c363311721a4bcbed7ea56a28c82350486591a9a1fd5032238339f02
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
